{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:51:18Z","timestamp":1783569078292,"version":"3.55.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s10620-020-06100-0","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T06:02:37Z","timestamp":1580796157000},"page":"897-905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction"],"prefix":"10.1007","volume":"65","author":[{"given":"Sarah","family":"Lechner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkeley N.","family":"Limketkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"6100_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/liv.13682","volume":"38","author":"P Marcellin","year":"2018","unstructured":"Marcellin P, Kutala BK. Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening. J Liver Int. 2018;38:2\u20136.","journal-title":"J Liver Int"},{"key":"6100_CR2","unstructured":"Fecal microbiota transplant as treatment of hepatic encephalopathy\u2014full text view\u2014ClinicalTrials.gov. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT03420482. Accessed 26th Jan 2019."},{"key":"6100_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jhep.2013.03.007","volume":"59","author":"J Rehm","year":"2013","unstructured":"Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013;59:160\u2013168.","journal-title":"J Hepatol"},{"key":"6100_CR4","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"JD Browning","year":"2004","unstructured":"Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387\u20131395.","journal-title":"Hepatology"},{"key":"6100_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","volume":"140","author":"CD Williams","year":"2011","unstructured":"Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124\u2013131.","journal-title":"Gastroenterology"},{"key":"6100_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-1-4615-4143-1_2","volume-title":"Mechanisms in the Pathogenesis of Enteric Diseases","author":"RD Berg","year":"1999","unstructured":"Berg RD. Bacterial translocation from the gastrointestinal tract. In: Paul PS, Francis DH, Benfield DA, eds. Mechanisms in the Pathogenesis of Enteric Diseases, vol. 2. Berlin: Springer; 1999:11\u201330."},{"key":"6100_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI88881","volume":"127","author":"Y Koyama","year":"2017","unstructured":"Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Investig. 2017;127:55\u201364.","journal-title":"J Clin Investig"},{"key":"6100_CR8","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1136\/gut.35.11.1648","volume":"35","author":"J Llovet","year":"1994","unstructured":"Llovet J, Bartoli R, Planas RE, et al. Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis. Gut. 1994;35:1648\u20131652.","journal-title":"Gut"},{"key":"6100_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.20632","volume":"41","author":"R Wiest","year":"2005","unstructured":"Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41:422\u2013433.","journal-title":"Hepatology"},{"key":"6100_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","volume":"60","author":"R Wiest","year":"2014","unstructured":"Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. Hepatology. 2014;60:197\u2013209.","journal-title":"Hepatology"},{"key":"6100_CR11","first-page":"321","volume":"13","author":"JP Arab","year":"2018","unstructured":"Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Hepatology. 2018;13:321\u2013350.","journal-title":"Hepatology"},{"key":"6100_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cmet.2009.09.006","volume":"10","author":"M Saberi","year":"2009","unstructured":"Saberi M, Woods N-B, de Luca C, et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab. 2009;10:419\u2013429.","journal-title":"Cell Metab"},{"key":"6100_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1172\/JCI11792","volume":"107","author":"JM Fleckenstein","year":"2001","unstructured":"Fleckenstein JM, Kopecko DJ. Breaching the mucosal barrier by stealth: an emerging pathogenic mechanism for enteroadherent bacterial pathogens. J Clin Investig. 2001;107:27\u201330.","journal-title":"J Clin Investig"},{"key":"6100_CR14","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1080\/10408398.2018.1506734","volume":"59","author":"MDC Ponce de Le\u00f3n-Rodr\u00edguez","year":"2019","unstructured":"Ponce de Le\u00f3n-Rodr\u00edguez MDC, Guyot J-P, Laurent-Babot C. Intestinal in vitro cell culture models and their potential to study the effect of food components on intestinal inflammation. Crit Rev Food Sci Nutr. 2019;59:3648\u20133666.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"6100_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2147\/DMSO.S163062","volume":"11","author":"A-S Kim","year":"2018","unstructured":"Kim A-S, Ko H-J. Plasma concentrations of zonulin are elevated in obese men with fatty liver disease. Diabetes Metab Syndr Obes: Targets Ther. 2018;11:149.","journal-title":"Diabetes Metab Syndr Obes: Targets Ther"},{"key":"6100_CR16","doi-asserted-by":"publisher","first-page":"17107","DOI":"10.3748\/wjg.v20.i45.17107","volume":"20","author":"L Pacifico","year":"2014","unstructured":"Pacifico L, Bonci E, Marandola L, Romaggioli S, Bascetta S, Chiesa C. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease. World J Gastroenterol WJG. 2014;20:17107.","journal-title":"World J Gastroenterol WJG"},{"key":"6100_CR17","doi-asserted-by":"publisher","first-page":"e0183282","DOI":"10.1371\/journal.pone.0183282","volume":"12","author":"A Nier","year":"2017","unstructured":"Nier A, Engstler AJ, Maier IB, Bergheim I. Markers of intestinal permeability are already altered in early stages of non-alcoholic fatty liver disease: studies in children. PloS One. 2017;12:e0183282.","journal-title":"PloS One"},{"key":"6100_CR18","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1172\/JCI90562","volume":"127","author":"A-M Yang","year":"2017","unstructured":"Yang A-M, Inamine T, Hochrath K, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Investig. 2017;127:2829\u20132841.","journal-title":"J Clin Investig"},{"key":"6100_CR19","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jcmgh.2016.04.007","volume":"2","author":"L Etienne-Mesmin","year":"2016","unstructured":"Etienne-Mesmin L, Vijay-Kumar M, Gewirtz AT, Chassaing B. Hepatocyte toll-like receptor 5 promotes bacterial clearance and protects mice against high-fat diet\u2013induced liver disease. Cell Mol Gastroenterol Hepatol. 2016;2:584\u2013604.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"6100_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nchembio.1864","volume":"11","author":"AS Devlin","year":"2015","unstructured":"Devlin AS, Fischbach MA. A biosynthetic pathway for a prominent class of microbiota-derived bile acids. Nat Chem Biol. 2015;11:685.","journal-title":"Nat Chem Biol"},{"key":"6100_CR21","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1631\/jzus.B1400327","volume":"16","author":"Y-F Nie","year":"2015","unstructured":"Nie Y-F, Hu J, Yan X-H. Cross-talk between bile acids and intestinal microbiota in host metabolism and health. J Zhejiang Univ. 2015;16:436\u2013446.","journal-title":"J Zhejiang Univ"},{"key":"6100_CR22","first-page":"1615","volume":"56","author":"DE Jones","year":"2007","unstructured":"Jones DE. Pathogenesis of primary biliary cirrhosis. Gut. 2007;56:1615\u20131624.","journal-title":"Gut"},{"key":"6100_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/pathogens3010014","volume":"3","author":"P G\u00e9rard","year":"2013","unstructured":"G\u00e9rard P. Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens. 2013;3:14\u201324.","journal-title":"Pathogens"},{"key":"6100_CR24","doi-asserted-by":"publisher","first-page":"1254766","DOI":"10.1126\/science.1254766","volume":"349","author":"MS Donia","year":"2015","unstructured":"Donia MS, Fischbach MA. Small molecules from the human microbiota. Science. 2015;349:1254766.","journal-title":"Science"},{"key":"6100_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cell.2013.12.018","volume":"156","author":"L Guo","year":"2014","unstructured":"Guo L, Karpac J, Tran SL, Jasper H. PGRP-SC2 promotes gut immune homeostasis to limit commensal dysbiosis and extend lifespan. Cell. 2014;156:109\u2013122.","journal-title":"Cell"},{"key":"6100_CR26","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","volume":"67","author":"R Wiest","year":"2017","unstructured":"Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. J Hepatol. 2017;67:1084\u20131103.","journal-title":"J Hepatol"},{"key":"6100_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","volume":"64","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. Hepatology. 2016;64:399\u2013408.","journal-title":"Hepatology"},{"key":"6100_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","volume":"24","author":"KS T\u00f8lb\u00f8l","year":"2018","unstructured":"T\u00f8lb\u00f8l KS, Kristiansen MN, Hansen HH, et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol: WJG. 2018;24:179.","journal-title":"World J Gastroenterol: WJG"},{"key":"6100_CR29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.cmet.2017.04.013","volume":"25","author":"E Grasset","year":"2017","unstructured":"Grasset E, Puel A, Charpentier J, et al. A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism. Cell Metab. 2017;25:1075\u20131090.","journal-title":"Cell Metab"},{"key":"6100_CR30","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1206095","volume":"332","author":"JL Round","year":"2011","unstructured":"Round JL, Lee SM, Li J, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. 2011;332:974\u2013977.","journal-title":"Science"},{"key":"6100_CR31","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s12275-017-7340-4","volume":"55","author":"S Yoon","year":"2017","unstructured":"Yoon S, Yu J, McDowell A, Kim SH, You HJ, Ko G. Bile salt hydrolase-mediated inhibitory effect of Bacteroides ovatus on growth of Clostridium difficile. J Microbiol. 2017;55:892\u2013899.","journal-title":"J Microbiol"},{"key":"6100_CR32","first-page":"129","volume":"11","author":"JR Kerr","year":"1999","unstructured":"Kerr JR. Bacterial inhibition of fungal growth and pathogenicity. Microb Ecol Health Dis. 1999;11:129\u2013142.","journal-title":"Microb Ecol Health Dis"},{"key":"6100_CR33","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1128\/iai.60.9.3509-3512.1992","volume":"60","author":"J Harp","year":"1992","unstructured":"Harp J, Chen W, Harmsen A. Resistance of severe combined immunodeficient mice to infection with Cryptosporidium parvum: the importance of intestinal microflora. Infect Immun. 1992;60:3509\u20133512.","journal-title":"Infect Immun"},{"key":"6100_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.femsre.2004.09.003","volume":"29","author":"M Begley","year":"2005","unstructured":"Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. J FEMS Microbiol Rev. 2005;29:625\u2013651.","journal-title":"J FEMS Microbiol Rev"},{"key":"6100_CR35","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.3389\/fmicb.2015.01543","volume":"6","author":"M Francino","year":"2016","unstructured":"Francino M. Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances. Front Microbiol. 2016;6:1543.","journal-title":"Front Microbiol"},{"key":"6100_CR36","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nrmicro2164","volume":"7","author":"M Rupnik","year":"2009","unstructured":"Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7:526.","journal-title":"Nat Rev Microbiol"},{"key":"6100_CR37","doi-asserted-by":"publisher","first-page":"G1018","DOI":"10.1152\/ajpgi.00245.2016","volume":"311","author":"S Bluemel","year":"2016","unstructured":"Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol. 2016;311:G1018\u2013G1036.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"6100_CR38","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrd2619","volume":"7","author":"C Thomas","year":"2008","unstructured":"Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008;7:678.","journal-title":"Nat Rev Drug Discov"},{"key":"6100_CR39","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.3748\/wjg.v23.i25.4491","volume":"23","author":"FR Ponziani","year":"2017","unstructured":"Ponziani FR, Zocco MA, D\u2019Aversa F, Pompili M, Gasbarrini A. Eubiotic properties of rifaximin: disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol: WJG. 2017;23:4491.","journal-title":"World J Gastroenterol: WJG"},{"key":"6100_CR40","first-page":"CD008716","volume":"11","author":"RG McGee","year":"2011","unstructured":"McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011;11:CD008716.","journal-title":"Cochrane Database Syst Rev"},{"key":"6100_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/hep.28121","volume":"63","author":"D Kao","year":"2016","unstructured":"Kao D, Roach B, Park H, et al. Fecal microbiota transplantation in the management of hepatic encephalopathy. Hepatology. 2016;63:339\u2013340.","journal-title":"Hepatology"},{"key":"6100_CR42","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/hep.29306","volume":"66","author":"JS Bajaj","year":"2017","unstructured":"Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology. 2017;66:1727\u20131738.","journal-title":"Hepatology"},{"key":"6100_CR43","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1053\/j.gastro.2019.01.033","volume":"156","author":"JS Bajaj","year":"2019","unstructured":"Bajaj JS, Fagan A, Gavis EA, Kassam Z, Sikaroodi M, Gillevet PM. Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis. Gastroenterology. 2019;156:1921\u20131923.","journal-title":"Gastroenterology"},{"key":"6100_CR44","unstructured":"Fecal microbiota transplantation (FMT) in the management of hepatic encephalopathy (HE): a pilot study\u2014full text view\u2014ClinicalTrials.gov. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02255617. Accessed 26th Jan 2019."},{"key":"6100_CR45","unstructured":"Fecal transplant for hepatic encephalopathy\u2014full text view\u2014ClinicalTrials.gov. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT03439982. Accessed 26th Jan 2019."},{"key":"6100_CR46","unstructured":"Oral fecal transplant in cirrhosis\u2014full text view\u2014ClinicalTrials.gov. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT03152188. Accessed 26th Jan 2019."},{"key":"6100_CR47","unstructured":"A comparison of fecal microbiota transplantation and steroid therapy in patients with severe alcoholic hepatitis\u2014full text view\u2014ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03091010. Accessed 26th Jan 2019."},{"key":"6100_CR48","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","volume":"75","author":"WC Maddrey","year":"1978","unstructured":"Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75:193\u2013199.","journal-title":"Gastroenterology"},{"key":"6100_CR49","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","volume":"372","author":"MR Thursz","year":"2015","unstructured":"Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372:1619\u20131628.","journal-title":"N Engl J Med"},{"key":"6100_CR50","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1053\/j.gastro.2008.08.057","volume":"135","author":"NC Boetticher","year":"2008","unstructured":"Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology. 2008;135:1953\u20131960.","journal-title":"Gastroenterology"},{"key":"6100_CR51","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/hep.20206","volume":"39","author":"S Naveau","year":"2004","unstructured":"Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39:1390\u20131397.","journal-title":"Hepatology"},{"key":"6100_CR52","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/ajg.2014.154","volume":"109","author":"V Singh","year":"2014","unstructured":"Singh V, Sharma AK, Narasimhan RL, Bhalla A, Sharma N, Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol. 2014;109:1417.","journal-title":"Am J Gastroenterol"},{"key":"6100_CR53","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4254\/wjh.v9.i12.567","volume":"9","author":"P Fung","year":"2017","unstructured":"Fung P, Pyrsopoulos N. Emerging concepts in alcoholic hepatitis. World J Hepatol. 2017;9:567.","journal-title":"World J Hepatol"},{"key":"6100_CR54","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/gutjnl-2015-310585","volume":"65","author":"M Llopis","year":"2016","unstructured":"Llopis M, Cassard A, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut. 2016;65:830\u2013839.","journal-title":"Gut"},{"key":"6100_CR55","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jhep.2016.11.008","volume":"66","author":"G Ferrere","year":"2017","unstructured":"Ferrere G, Wrzosek L, Cailleux F, et al. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice. J Hepatol. 2017;66:806\u2013815.","journal-title":"J Hepatol"},{"key":"6100_CR56","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","volume":"15","author":"CA Philips","year":"2017","unstructured":"Philips CA, Pande A, Shasthry SM, et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol. 2017;15:600\u2013602.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6100_CR57","doi-asserted-by":"publisher","first-page":"bcr-2017\u2013222310","DOI":"10.1136\/bcr-2017-222310","volume":"2017","author":"CA Philips","year":"2017","unstructured":"Philips CA, Phadke N, Ganesan K, Augustine P. Healthy donor faecal transplant for corticosteroid non-responsive severe alcoholic hepatitis. BMJ Case Rep. 2017;2017:bcr-2017\u2013222310.","journal-title":"BMJ Case Rep"},{"key":"6100_CR58","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12664-018-0859-4","volume":"37","author":"CA Philips","year":"2018","unstructured":"Philips CA, Phadke N, Ganesan K, Ranade S, Augustine P. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis. Indian J Gastroenterol. 2018;37:215\u2013225.","journal-title":"Indian J Gastroenterol"},{"key":"6100_CR59","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1056\/NEJMra1506330","volume":"375","author":"KN Lazaridis","year":"2016","unstructured":"Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med. 2016;375:1161\u20131170.","journal-title":"N Engl J Med"},{"key":"6100_CR60","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","volume":"65","author":"J Sabino","year":"2016","unstructured":"Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65:1681\u20131689.","journal-title":"Gut"},{"key":"6100_CR61","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","volume":"66","author":"M Kummen","year":"2017","unstructured":"Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut. 2017;66:611\u2013619.","journal-title":"Gut"},{"key":"6100_CR62","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.3748\/wjg.v23.i25.4548","volume":"23","author":"L Bajer","year":"2017","unstructured":"Bajer L, Kverka M, Kostovcik M, et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol. 2017;23:4548\u20134558.","journal-title":"World J Gastroenterol"},{"key":"6100_CR63","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.12232","volume":"37","author":"JH Tabibian","year":"2013","unstructured":"Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis\u2014a pilot study. Aliment Pharmacol Ther. 2013;37:604\u2013612.","journal-title":"Aliment Pharmacol Ther"},{"key":"6100_CR64","doi-asserted-by":"publisher","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","volume":"25","author":"S Rahimpour","year":"2016","unstructured":"Rahimpour S, Nasiri-Toosi M, Khalili H, Ebrahimi-Daryani N, Nouri-Taromlou MK, Azizi Z. A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. J Gastrointest Liver Dis. 2016;25:457\u2013464.","journal-title":"J Gastrointest Liver Dis JGLD"},{"key":"6100_CR65","doi-asserted-by":"publisher","first-page":"438","DOI":"10.14218\/JCTH.2018.00033","volume":"6","author":"CA Philips","year":"2018","unstructured":"Philips CA, Augustine P, Phadke N. Healthy donor fecal microbiota transplantation for recurrent bacterial cholangitis in primary sclerosing cholangitis\u2014a single case report. J Clin Transl Hepatol. 2018;6:438\u2013441.","journal-title":"J Clin Transl Hepatol"},{"key":"6100_CR66","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","volume":"114","author":"JR Allegretti","year":"2019","unstructured":"Allegretti JR, Kassam Z, Carrellas M, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol. 2019;114:1071\u20131079.","journal-title":"Am J Gastroenterol"},{"key":"6100_CR67","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/hep.28256","volume":"63","author":"CY Ponsioen","year":"2016","unstructured":"Ponsioen CY, Chapman RW, Chazouilleres O, et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process. Hepatology. 2016;63:1357\u20131367.","journal-title":"Hepatology"},{"key":"6100_CR68","unstructured":"World Health Organization (2017) World Health Organization & Global Hepatitis Programme. Global hepatitis report, 2017."},{"key":"6100_CR69","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","volume":"3","author":"D Razavi-Shearer","year":"2018","unstructured":"Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383\u2013403.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6100_CR70","first-page":"2361963","volume":"2018","author":"R Yang","year":"2018","unstructured":"Yang R, Xu Y, Dai Z, Lin X, Wang H. The immunologic role of gut microbiota in patients with chronic HBV infection. J Immunol Res. 2018;2018:2361963.","journal-title":"J Immunol Res"},{"key":"6100_CR71","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1073\/pnas.1424775112","volume":"112","author":"H-H Chou","year":"2015","unstructured":"Chou H-H, Chien W-H, Wu L-L, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. Proc Natl Acad Sci. 2015;112:2175\u20132180.","journal-title":"Proc Natl Acad Sci"},{"key":"6100_CR72","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1002\/hep.29008","volume":"65","author":"YD Ren","year":"2017","unstructured":"Ren YD, Ye ZS, Yang LZ, et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. Hepatology. 2017;65:1765\u20131768.","journal-title":"Hepatology"},{"key":"6100_CR73","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261\u2013283.","journal-title":"Hepatology"},{"key":"6100_CR74","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"6100_CR75","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jhep.2015.02.041","volume":"62","author":"V Ratziu","year":"2015","unstructured":"Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62:S65\u2013S75.","journal-title":"J Hepatol"},{"key":"6100_CR76","unstructured":"Fecal microbiota transplantation (FMT) in nonalcoholic steatohepatitis (NASH). A pilot study\u2014full text view\u2014ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02469272 Accessed 2nd Feb 2019."},{"key":"6100_CR77","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","volume":"7","author":"D Zhou","year":"2017","unstructured":"Zhou D, Pan Q, Shen F, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 2017;7:1529.","journal-title":"Sci Rep"},{"issue":"11","key":"6100_CR78","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3390\/nu9111220","volume":"9","author":"Chien-Chao Chiu","year":"2017","unstructured":"Chiu CC, Ching YH, Li YP, et al. Nonalcoholic fatty liver disease is exacerbated in high-fat diet-fed gnotobiotic mice by colonization with the gut microbiota from patients with nonalcoholic steatohepatitis. Nutrients 2017;9.","journal-title":"Nutrients"},{"key":"6100_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/jcar.JCar_9_16","volume":"16","author":"YA Ghouri","year":"2017","unstructured":"Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.","journal-title":"J Carcinog"},{"key":"6100_CR80","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.transproceed.2016.01.077","volume":"48","author":"M Gr\u0105t","year":"2016","unstructured":"Gr\u0105t M, Wronka KM, Krasnodebski M, et al. Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis. Transplant Proc. 2016;48:1687\u20131691.","journal-title":"Transplant Proc"},{"key":"6100_CR81","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jhep.2012.06.011","volume":"57","author":"HL Zhang","year":"2012","unstructured":"Zhang HL, Yu LX, Yang W, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol. 2012;57:803\u2013812.","journal-title":"J Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06100-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06100-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06100-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T14:28:45Z","timestamp":1650205725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06100-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["6100"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06100-0","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"4 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"None","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}